The prescription eye care product manufacturer said the product, Prolensa, is a low concentration of its bromfenac compound in a modified ophthalmic solution that enhances eye tissue penetration.
The company currently markets four products, including treatments for post-cataract surgery, glaucoma and allergies. The company plans to submit the new drug application for Prolensa to the U.S. Food and Drug Administration in the first quarter of next year.
Related Articles on Ophthalmology:
Sterile Processing of Eye Instruments: Q&A With Nancy Jo Vinson
New Wisconsin Eye Surgery Center Coming to Green Bay
SC Eye Surgeon to Broadcast Laser Cataract Surgery From ASC
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
